[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"viral-lung-infection-and-acute-respiratory-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:viral-lung-infection-and-acute-respiratory-failure":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100487236","phase-3-efficacy-and-safety-of-tozorakimab-in-patients-hospitalised-for-viral-lung-infection-requiring-supplemental-oxygen-100487236",false,"NCT05624450","Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen","A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen","TILIA","Inclusion Criteria:\n\n* Adult participants ≥ 18 years old at the time of signing the informed consent form.\n* Patients hospitalised with viral lung infection.\n* Hypoxaemia requiring treatment with supplemental O2.\n\nHypoxaemia is defined as:\n\nSpO2 ≤ 90% OR\n\nSpO2 ≤ 92% AND one or both of the following:\n\nRadiographic infiltrates by CXR\u002FCT compatible with viral lung infection per investigator judgement.\n\nUse of accessory muscles of respiration or RR (respiratory rate) \\> 22.\n\n\\- Patient remains hypoxaemic at randomisation requiring treatment with supplemental oxygen.\n\nExclusion Criteria:\n\n* Known fungal or parasitic lung infection, aspiration lung infection, lung abscess, or evidence of septic shock. Bacterial co-infection is allowed, unless, in the opinion of the investigator, bacterial infection defines the severity of the participant's condition.\n* Hypoxaemia caused primarily by extrapulmonary insult or by lung injury of non-infective aetiology.\n* Ongoing IMV\u002FECMO at randomisation.","ALL","18 Years",{"count":20,"type":21},3527,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV\u002FECMO.",[27],"Viral Lung Infection and Acute Respiratory Failure",[29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44],"Acute Respiratory Failure","Acute Respiratory Distress Syndrome","Viral lung infection","Tozorakimab","Supplemental Oxygen","IL-33","COVID-19","SARS-CoV-2","Coronavirus Infections","Virus Diseases","SARS Coronavirus","MEDI3506","Respiratory Tract Infections","Infections","Lung Diseases","Influenza","RECRUITING","2026-08-27",{"date":48,"type":49},"2026-08-28","ACTUAL",{"date":51,"type":49},"2022-12-13",{"date":53,"type":21},"2027-11-04",{"name":55,"class":56},"AstraZeneca","INDUSTRY",468]